Drugs.com - Clinical Trials

Higher Dose of Wegovy Provided Average Weight Loss of 21% in People with Obesity With a Third Achieving 25% or More

Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the...

Jun 21, 2025 - 03:00
 0
Higher Dose of Wegovy Provided Average Weight Loss of 21% in People with Obesity With a Third Achieving 25% or More
Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the...
Read More

Tags:

Previous Article

Emirates and Uber sign strategic partnership

Next Article

Lilly to Offer All Approved Doses of Zepbound (tirzepatide) Single-Dose Vials Th...

Related Posts

Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia

Bristol Myers Squibb Announces Topline Results from Pha...

May 12, 2025  0

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Precision BioSciences Receives U.S. FDA Fast Track Desi...

May 12, 2025  0

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

Aldeyra Therapeutics Achieves Primary Endpoint in Phase...

May 12, 2025  0